津力达颗粒治疗2型糖尿病（气阴两虚挟瘀证）的临床研究

《津力达颗粒治疗2型糖尿病（气阴两虚挟瘀证）的临床研究》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、学校代号10199学号20124118067硕士学位论文津力达颗粒治疗2型糖尿病(气阴两虚挟瘀证)的临床研究JinLiDaparticlesinthetreatmentofpatientswithtype2diabetesmellitus(QiYinliangxujiayuzheng)clinicalresearch学位申请人宿美导师姓名职称朴春丽教授专业名称中医内科学研究方向消渴病的研究培养方式全日制申请学位类型专业学位论文提交日期2014年4月分类号密级ＵＤＣ编号硕±学位论文

2、津力达燕松治疗２型搪尿病（气阴两虚挟痴证）的临床研究Ｊ＊ｉｎＬｉＤａａｒｔｉｃｌｅｓｉｎｔｈｅ化ｅａｔｍｅｎｔｏｆｐｐａ村ｅｎｔｓｗｉｔｈｔｅ２ｄｉａｂｅｔｅｓｍｅｌｌｉｔｕｓｉｙｐ（ＱＹｉｎｌｉａｎｘｕｉａｕｚｈｅｎｃｌｉｎｉｃａｌｒｅｓｅａｒｃｈｇｊｙｇ）宿美指导教师姓名：朴春丽教授（长春中医药大学）申请学位级别：硕±专业名称：中医内科学研究方向：消渴病的研究论女提交日期：２０１４年４月论义笞辩日期：２０１４年６月

3、学位授予单位：长春中医药大争提交确认：作者签名牲导师签长春中医药大学学位论文原创性声明，是个人在导师的指导下本人郑重声明：所呈交的学位论文，独立进行研究工作所取得的成果。除文中已经特别加Ｕ注明引用的內容外，本论文不含任何其他个人或集体已经发表或撰写过的作品成果。对本文的研究做出重要贡献的个人和集体，均已在文中明确方式标明并致谢。本人完全意识到本声明的法律结果由本人承担。学位论义作者答名年备月三？Ｈ关于学位论文知识产权归属的声明本人郑重声明助：所呈交的学位论

4、文，是本人在导师指导下自选课题或导师承担的国家立项资一助进行所取得的成果知权归属的划课题的部，系人在导师指导和资下独立研究工作，识产计分本一权医。特声明声为长中学和人导师所有此，本明的切法律责任由本人承担。春药大本论专化者絡名巧导教师祭《年月三曰７多＞玄于声明关位论文使用授权的学位文的规定留向有机交本人完全了解春中医药大学有关保留使用学论，同意学校保并关构送长。权中医１＾学文的全或论文的和电子，允许被查阅和借闽本人授长春药大学可将本位论部复印件版人采、缩其他本学论文。内编有库

5、进行检索，可Ｗ用影印印或复印手段保存和汇编位部分容关数据文密后应守规定（保密论在解遵此）论义作者答么，指导教师蒋名曠，、）备《月目年如ａ长春中医药大学2015届硕士学位论文目录目录中文摘要································································································1英文摘要·······················································

6、·········································2英文缩略语·····························································································3前言································································································4文献综述············

7、····················································································61中医对消渴的认识·················································································622型糖尿病的脾系病因病机研究·································································

8、73健脾法的理法研究·················································································94总结与展望··························································································12临床研究··············